Buzz-Street View: Device blues can't dim J&J's pipeline glow
JNJ•J&J beats estimates as medical device unit underperforms
Johnson & Johnson (JNJ.N) said on Wednesday that its medical device unit underperformed in the second quarter, even as strong sales of Tremfya for autoimmune conditions and cancer treatment Darzalex helped it beat Wall Street estimates.
Twenty-seven analysts rate the stock "Buy" on average; median PT $270 - data compiled by LSEG.
Analysts see support from immunology, launches and pipeline
J.P. Morgan ("Neutral") expects J&J's immunology business to remain strong, with Icotyde contributing more growth by 2027, but weaker demand for Impella heart pumps may weigh on second-half results, putting the focus on the heart-device unit's recovery.
Morgan Stanley ("Overweight," PT: $294) says J&J continues to evaluate all options for separating its orthopedics business, which remains on track for completion in mid-2027.
Leerink Partners ("Outperform," PT: $276) says that Icotyde, its treatment for plaque psoriasis, is outperforming most recent launches, and expects to see key late-stage trial data that could support approval in a form of kidney cancer.
RBC Capital Markets ("Outperform," PT: $287) says J&J's new drug launches support faster growth from 2027 and strengthen its goal of becoming the top oncology company by 2030, while delivering double-digit growth by decade-end.
